T65.5X2A Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter

Name of the Condition

• Toxic Effect of Nitroglycerin and Other Nitric Acids and Esters, Intentional Self-Harm, Initial Encounter

Summary

This condition describes adverse health effects resulting from intentional self-harm exposure to nitroglycerin or other nitric acids and esters, with an initial encounter for treatment. These substances, known for their vasodilatory properties, can cause systemic toxicity, including hypotension, methemoglobinemia, or metabolic disturbances when absorbed in excessive amounts through deliberate ingestion, inhalation, or dermal contact.

Causes

The toxic effect is caused by intentional self-harm exposure to nitroglycerin or related nitric acids and esters, which may occur through deliberate ingestion, inhalation of vapors, or skin absorption. Common sources include pharmaceutical preparations (e.g., for angina), industrial chemicals, or other nitric acid ester-containing materials. Deliberate overdose or misuse of these substances leads to poisoning.

Risk Factors

• Intentional overdose of nitroglycerin-containing medications.
• Deliberate exposure to industrial nitric acid esters.
• Misuse or abuse of nitroglycerin products.
• Access to nitroglycerin or related compounds without supervision.

Symptoms

• Headache, dizziness, or lightheadedness due to vasodilation.
• Hypotension, tachycardia, or syncope.
• Nausea, vomiting, or abdominal pain.
• Methemoglobinemia, leading to cyanosis or dyspnea.
• Flushing, sweating, or skin irritation.
• Seizures or cardiovascular collapse in severe cases.

Diagnosis

Diagnosis is based on clinical presentation, history of intentional exposure, and laboratory findings. Clinical assessment includes evaluating symptoms of vasodilation, hypotension, or methemoglobinemia. Laboratory tests may include blood gas analysis to detect methemoglobin levels, electrolyte panels, and cardiac monitoring. Toxicology screening can confirm exposure to nitroglycerin or related compounds.

Treatment Options

Treatment focuses on stabilizing the patient and managing symptoms. Initial care includes airway support, oxygen therapy, and intravenous fluids to address hypotension. Methemoglobinemia may require methylene blue administration. Cardiovascular monitoring and supportive care are essential. In severe cases, intensive care unit admission and advanced interventions (e.g., vasopressors) may be necessary.

Prognosis and Follow-Up

Prognosis depends on the severity of exposure and timely intervention. Mild cases often resolve with supportive care, while severe toxicity may lead to prolonged hospitalization or complications. Follow-up includes monitoring for delayed effects, mental health evaluation for self-harm risk, and education on substance safety. Long-term outcomes vary based on the extent of organ involvement.

Complications

• Severe hypotension or cardiovascular collapse.
• Persistent methemoglobinemia.
• Neurological damage from hypoxia or seizures.
• Organ injury (e.g., liver, kidney) from systemic toxicity.
• Psychological sequelae related to self-harm.

Lifestyle & Prevention

Prevention involves secure storage of nitroglycerin and related substances, proper disposal of unused medications, and education on safe handling. For individuals at risk of self-harm, access to mental health support and crisis intervention is critical. Avoiding unsupervised access to these compounds reduces exposure risk.

When to Seek Professional Help

Seek immediate medical attention if intentional exposure to nitroglycerin or nitric acids/esters occurs, or if symptoms like severe dizziness, fainting, or difficulty breathing develop. Emergency care is necessary for suspected overdose or self-harm, even if symptoms are mild initially.

Tips for Medical Coders

Document the intent (intentional self-harm) and encounter type (initial) clearly. Code T65.5X2A is specific to initial encounters for intentional self-harm. Ensure clinical documentation supports the diagnosis, including details of exposure, symptoms, and treatment. Verify that the code aligns with the patient’s clinical presentation and encounter context.